Archive RSS Feed: CNN Business news and FORTUNE Magazine

Recipe for a meltdown

With the S&P down over 10% from its October record high, TV pundits and Wall Street strategists are blaming the most obvious culprits for the sudden reversal of fortune, chiefly the subprime crisis and the looming threat of a recession. But it's neither the credit crunch, nor a slowing economy -- nor a third hobgoblin, the weak dollar -- that pushed the markets into correction territory Monday.

Enron suit: A new tempest for Citi?

"When Enron blows up, will it be worse than Long-Term Capital?"

'Tis the season for insider stock buys

Despite the uncertainty over a holiday shopping season that threatens to squash retail profits in a melee of discounting, some executives and directors are finding bargains in their companies' beaten down stock.

Stock maestro's picks: British pubs

They call him the L-Train. Larry Robbins is the driven, blunt, larger-than-life founder and CEO of Glenview Capital who manages $7 billion a year and has been honored as one of Trader Monthly's top 100 Hedge Fund Traders. At this year's Value Investing Congress held in Manhattan, which drew investing luminaries like Bill Ackman and Leon Cooperman, he told a crowd of fellow hedgies that his fund is adapting to uncertain times.

In defense of oil

Oil companies are blamed (unjustly) for high gas prices, loathed for profiting from them, and criticized for their environmental record. So it's no wonder that most industry CEOs have made themselves scarce. Chevron's David O'Reilly is the exception. He regularly talks to reporters and appears on television to answer questions about Chevron and the industry.

Citi stake is just the beginning

So you're lousy with petrocash or other export-driven windfalls, and itching to put your depreciating dollars to work. Where to start? Here's Fortune's handy tip sheet:

Lampert can't reverse Sears' decline

Call it the Lampert discount.

A radical plan to lower drug costs

What to do about the high cost of drugs? A cadre of academics and economists has a radical new answer: Take away the exclusive product patents the government grants a new drug and replace them with cash awards to the innovating company.

The curse of WiMax

A few weeks ago, Sprint Nextel and Clearwire, an upstart wireless company backed by cellular pioneer Craig McCaw, severed plans to jointly build wireless broadband services, a venture that was supposed to accelerate the nationwide rollout of a technology called WiMax.